

## MOLECULAR AND CELLULAR BIOLOGY

---

### **Sarcolemmal Remodelling in Cardiac Hypertrophy due to Volume Overload**

**Naranjan S. Dhalla**, St. Boniface General Hospital Research Center, Winnipeg, Canada

### **A General Paradigm of Progress of Heart Failure to the Advanced Stage with the Cleavage and Translocation of Myocardial Dystrophin**

**Teruhiko Toyo-oka**, University of Tokyo, P/Graduate School of Medicine, Tokyo, Japan

### **HIF 1 $\alpha$ : A Key Early Trigger of Ventricular Remodeling Following Myocardial Infarction**

**Peter M. Buttrick**, University of Illinois, Chicago, IL, U.S.A.

### **Pathophysiology of Cardiac Protein Kinase C**

**Mohamed Boutjdir**, NY Harbor Healthcare System, Brooklyn, NY, U.S.A.

### **Heat Shock Proteins and Cardiovascular Disease**

**Anne Knowlton**, University of California, Davis, CA, U.S.A.

### **Protective Effects of Uroguanylin on Cardiovascular Disease in Dahl-Iwai Salt Sensitive Rats**

**Yasunori Momose**, Toho University, Funabashi, Chiba, Japan

## VASCULAR BIOLOGY, ENDOTHELIAL FUNCTION I

---

### **Vascular Remodeling in Intimal Stress and Strain. A Study in Rats**

**Marcos A. Rossi**, University of Sao Paulo, Ribeirao Preto, S.P., Brazil

### **Therapeutic Potential of Blockade of the Urotensin II System in Cardiovascular Disease**

**Henry Krum**, Monash University / Alfred Hospital, Melbourne, Victoria, Australia

### **Matrix Metalloproteinases and the Making of Blood Vessels**

**Zorina S. Galis**, Emory University School of Medicine, Atlanta, GA, U.S.A.

### **Vascular Effects of Physical Exercise. Lessons from Animal Models**

**Georg Kojda**, Universitätsklinikum, Dusseldorf, Germany

### **Arterial Stiffness: Improvement Through Changes In Lifestyle**

**Charalambos Vlachopoulos**, Hippokration Hospital Athens Medical School, Athens, Greece

### **Estradiol and Vascular Healing: A Promising Therapeutic Strategy**

**Jean-Francois Tanguay**, Montreal Heart Institute, Montreal, Quebec, Canada

### **The Role of Mitochondria in the Pathogenesis and Treatment of Vascular Remodeling; Novel Pharmacologic Targets and Treatment Strategies**

**Evangelos D. Michelakis**, University of Alberta, Edmonton, AB, Canada

**Controlling Inflammatory Cell Activation and Restoring Endothelial Cell Function During Oxidative Stress Through Novel Cellular Targets**

**Kenneth Maiese**, Wayne State University School of Medicine, Detroit, MI, U.S.A.

**VASCULAR BIOLOGY, ENDOTHELIAL FUNCTION II**

---

**Is Expressional Upregulation of the Endothelial NO Synthase Gene a Practical Approach to Prevent Vascular Disease?**

**Ulrich Forstermann**, Johannes Gutenberg University, Mainz, Germany

**NF- $\kappa$ B Signaling in Vascular Repair**

**Zhong-qun Yan**, Karolinska Hospital, Stockholm, Sweden

**Endothelial-Myocyte Uncoupling in Heart Failure: Role of Matrix**

**Suresh C. Tyagi**, University of Louisville School of Medicine, Louisville, KY, U.S.A.

**Role of Angiotensin II, Mechanical Pressure, and Oxidative Stress in Endothelial Dysfunction in Patients with Hypertension**

**Yukihito Higashi**, Graduate School of Biomedical Sciences, Minami-ku, Hiroshima, Japan

**The Genetic Basis of Endothelial Dysfunction: "Light and Shadows"**

**Gian Paolo Rossi**, Clinica Medica, Padova, Italy

**Cardioprotective Effect of Poly(ADP-Ribose) Polymerase Inhibition in Reperfusion Injury and in Heart Failure**

**Csaba Szabo**, Inotek Corporation, Beverly, MA, U.S.A.

**Respective Role of Nitric Oxide and Prostaglandins in Endothelial Dysfunction**

**Laurent Belhassen**, Hopital Prive d'Antony, Antony, France

**GENETIC STUDIES**

---

**Reversal of the Maladaptive Fetal Gene Program Following Therapy with Cardiac Contractility Modulation Non-Excitatory Electric Signals**

**Hani N. Sabbah**, Henry Ford Heart & Vascular Institute, Detroit, MI, U.S.A.

**Abnormalities of Sarcolemmal-Sarcomeric Linkage Cause Dilated Cardiomyopathy**

**Jeffrey A. Towbin**, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, U.S.A.

**Dilated Cardiomyopathy: A Disease of the Costamere**

**Neil Bowles**, Baylor College of Medicine, Feigin Center, Houston, TX, U.S.A.

**Optical Imaging of Vascular Gene Expression**

**Xiaoming Yang**, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.

**Genetic Alteration in Guanylyl Cyclase-/Natriuretic Peptide Receptor-A Defines Novel Target for Cardiovascular Disease States**

**Kailash N. Pandey**, Tulane University School of Medicine, New Orleans, LA, U.S.A.

**Genotype- and Mutation-Phenotype Correlation in the Long QT Syndrome**  
**Wataru Shimizu**, National Cardiovascular Center, Suita, Osaka, Japan

## **GENE AND CELL BASED THERAPIES**

---

### **Myogenesis: Enabling Technologies**

**Roger J. Laham**, BIDMC / Harvard Medical School, Boston, MA, U.S.A.

### **In Vivo MR Evaluation of Embryonic Stem Cells in the Injured Murine Heart**

**Phillip C. Yang**, Stanford University Medical Center, Stanford, CA, U.S.A.

### **Regeneration Therapy for Cardiovascular Diseases Using G-CSF**

**Hisayoshi Fujiwara**, Gifu University School of Medicine, Gifu, Japan

### **Reviewing the Field of Cell Therapy for Angiomyogenesis**

**Shmuel Fuchs**, Rabin Medical Center, Petach Tikva, Israel

### **Therapeutic Angiogenesis for the Treatment of Ischemic Peripheral and Heart Disease**

**Ryuichi Morishita**, Osaka University, School of Medicine, Suita, Japan

### **Transcatheter Stem Cell Therapy of Acute Myocardial Infarction**

**Junbo Ge**, Zhongshan Hospital, Fudan University, Shanghai, P.R. China

### **Stem Cell Therapy for Myocardial Repair: A Status Report**

**Raj R. Makkar**, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.

### **Stem Cells for Myocardial Neovascularization**

**Silviu Itescu**, College of Physicians & Surgeons of Columbia University, New York, NY, U.S.A.

### **Roles of Hepatocyte Growth Factor and Mast Cells in Thrombosis and Angiogenesis**

**Akira Matsumori**, Kyoto University Graduate School of Medicine, Kyoto, Japan

### **The Role of Progenitor Cells in Vascular Disease**

**Noel M. Caplice**, Mayo Clinic, Rochester, MN, U.S.A.

### **Job Descriptions for Cells to be Provided for Cardiac Repair**

**Christian C. Haudenschield**, U.S.A.

## ECHOCARDIOGRAPHY

---

### **Ultrasound Assessment of Cardiovascular Risk**

**Philip R. Liebson**, Rush Presbyterian-St. Luke's Medical Center, Chicago, IL, U.S.A.

### **The Current Role of Echocardiography in Heart Failure**

**Fausto J. Pinto**, University Hospital Sta Maria, Lisbon, Portugal

### **Novel Echocardiographic Technologies in Atrial Fibrillation**

**Itzhak Kronzon**, New York University Medical Center, New York, NY, U.S.A.

### **Clinical Usefulness of 3-D Echocardiography: Will It Replace 2-D Echo?**

**Navin C. Nanda**, University of Alabama at Birmingham, Birmingham, AL, U.S.A.

### **Noninvasive Ultrasound Techniques in the Evaluation of Clinical Cardiovascular Disease - State of the Art**

**Julius Gardin**, St. John Hospital and Medical Center, Detroit, MI, U.S.A.

### **Stress Echocardiography: State-of-the-Art**

**Patricia A. Pellikka**, Mayo Clinic, Rochester, MN, U.S.A.

### **Echocardiography for Risk Stratification of Age-Related Cardiovascular Diseases**

**Teresa S. Tsang**, Mayo Clinic, Rochester, MN, U.S.A.

### **Direct Myocardial Visualization with Substernal Epicardial Echocardiography- Lifesaving Examples of Altered Postoperative Care**

**Anthony P. Furnary**, Oregon Health Sciences University Hospital, Portland, OR, U.S.A.

### **Strain Rate Echocardiography in Ischemic Heart Disease**

**Cristina Pislaru**, Mayo Clinic, Rochester, MN, U.S.A.

## NEW DEVELOPMENTS IN CARDIAC IMAGING

---

### **Integration of Cardiac MRI, Cardiac CT Scanning, and Nuclear Cardiology in Clinical Assessment of Patients with Chronic CAD: Which Test for Which Patient?**

**Daniel S. Berman**, Cedars Sinai Medical Center, Los Angeles, CA, U.S.A.

### **Early Detection of Asymptomatic Coronary Artery Disease in Type II Diabetes: A Prospective Study of Combined Use of Electron Beam CT and Tc-99m Sestamibi Gated SPECT**

**Avijit Lahiri**, Northwick Park Hospital & Institute for Medical Research, Middlesex, England

### **Multi-Detector Spiral CT for the Evaluation of Coronary Artery Disease**

**Michael Motro**, Sheba Medical Center, Tel Hashomer, Israel

### **New Insight in the Evaluation of the Regional Left Ventricle Function**

**Francesco Fedele**, University of Rome "La Sapienza", Rome, Italy

## **Nuclear Cardiology: Which Gold Standard for Single Photon Emission Computed Tomography?**

**Paolo Marzullo**, Institute of Clinical Physiology, Pisa, Italy

## **Advances in Cardiovascular Molecular Imaging**

**Vasken Dilsizian**, University of Maryland School of Medicine, Baltimore, MD, U.S.A.

## **Role of Nuclear Cardiology in Identifying Patients Likely to Benefit From Coronary Revascularization**

**Rory Hachamovitch**, University of Southern California, Keck School of Medicine, Los Angeles, CA, U.S.A.

## **Nuclear Cardiology in the Management of Heart Disease in Diabetes Mellitus**

**Ronald G. Schwartz**, University of Rochester Medical Center, Rochester, NY, U.S.A.

## **Assessment of Myocardial Perfusion by Cardiac Magnetic Resonance**

**Luis J. Jimenez-Borreguero**, Hospital Universitario Principe Asturias, Alcala de Henares, Madrid, Spain

## **New Methods of Measuring Atrial Function**

**Brian D. Hoit**, Case Western Reserve University, Cleveland, OH, U.S.A.

# **ATHEROSCLEROSIS: PATHOGENESIS AND TREATMENT**

---

## **Nutrition, Inflammation, and Atherosclerosis**

**Rodolfo Paoletti**, University of Milan, Milan, Italy

## **Cross-Talk Between Dyslipidemia and Renin-Angiotensin System in Atherogenesis**

**Jawahar L. Mehta**, University of Arkansas for Medical Sciences, Little Rock, AR, U.S.A.

## **The Role of Stem/Progenitor Cells in the Pathogenesis of Atherosclerosis**

**Qingbo Xu**, St. George's Hospital Medical School, London, England

## **Anti-Inflammation Therapy Targeting Monocyte Chemoattractant Protein-1 as Novel Strategy to Treat Cardiovascular Disease**

**Kensuke Egashira**, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan

## **Novel NO Donors in the Treatment of Atherothrombotic Disorders**

**Paolo Gresele**, University of Perugia, Perugia, Italy

## **Infection and Inflammation in CAD - Where Do We Currently Stand?**

**Sandeep Gupta**, Whipps Cross and St. Bartholomew's Hospitals, Leytonstone, England

## **Mechanism of Atherosclerotic Plaque Instability: Role of Angiotensin II**

**Andrea Mezzetti**, University "G. d'Annunzio, Chieti-Pescara", Italy

## **Inflammation in Coronary Artery Disease - Lessons from Genetic and Proteomic Studies**

**Stefan Blankenberg**, Johannes Gutenberg-University Mainz, Mainz, Germany

## **Metalloproteinase Inhibition with Doxycycline to Prevent Atherosclerotic Plaque Rupture**

**David L. Brown**, Albert Einstein College of Medicine, New York, NY, U.S.A.

## **The Low Density Lipoprotein Receptor-Related Protein (LRP) is a Key Cellular Receptor in Atherosclerotic Plaque Formation and the Prothrombotic Transformation of the Lesion**

**Lina Badimon**, CSIC-ICCC, Barcelona, Spain

## **Atherosclerotic Plaque Stabilization: Potential Role for Immunomodulatory Therapy**

**Pål Aukrust**, Rikshospitalet, Oslo, Norway

## **Inflammation and Infection in Atherosclerosis**

**Salomon Amar**, Boston University Medical Center, Boston, MA, U.S.A.

## **EPIDEMIOLOGY OF ISCHEMIC HEART DISEASE**

---

### **Peculiarities of Low Risk Populations: Implication of Findings of the Seven Countries Study**

**Demosthenes B. Panagiotakos**, University of Athens, Glyfada, Attica, Greece

### **Cardioprotection with Beta Blockade: An Update**

**Barry F. Uretsky**, University of Texas Medical Branch at Galveston, Galveston, TX, U.S.A.

### **Advances in Coronary Heart Disease Among Indian Asians**

**Jaspal S. Kooner**, Imperial College, London, England

## **ACUTE CORONARY SYNDROMES, ACUTE MYOCARDIAL INFARCTION**

---

### **The Vulnerable Atheromatic Plaque: Detection and Treatment**

**Christodoulos Stefanadis**, Athens Medical School, Athens, Greece

### **Serial Analysis of the Ventricular Remodelling After Myocardial with the Multilisce TC and its Relation with the Anatomy of the Coronary Arteries**

**Sergio Dalla-Volta**, Universita Degli Studi di Padova, Padova, Italy

### **Optimal Management of Patients with Acute Myocardial Infarction Arriving at Hospitals Without On-Site Cardiac Surgery**

**Kirk N. Garratt**, Mayo Clinic, Rochester, MN, U.S.A.

### **Proteomics A New Technology for the Study of Biomarkers During the Acute Coronary Syndromes**

**Antonio J. Lopez Farre**, Hospital Clinico San Carlos, Madrid, Spain

### **What have the Introduction of Troponin and the New AMI Definition Done to the Coronary Care Unit? Impacts on Case Mix, Case Load and Patient Outcome**

**Doron Zahger**, Soroka University Medical Center, Beer Sheva, Israel

**Ischemic Preconditioning: Experimental Curiosity or Novel Biomarker?**

**Warren Laskey**, University of Maryland Medical Center, Baltimore, MD, U.S.A.

**Risk Stratification Post Myocardial Infarction: Implications from the INSPIRE Trial**

**John J. Mahmarian**, Baylor College of Medicine, Houston, TX, U.S.A

**ANTITHROMBOTIC AND ANTIPLATELET THERAPY**

---

**Identification and Treatment of Heparin-Induced Thrombocytopenia in the Cardiovascular Patient**

**James H. Chesebro**, Mayo Clinic Jacksonville, Jacksonville, FL, U.S.A.

**Heparin Induced Thrombocytopenia (HIT) in Acute Coronary Syndrome**

**Takanobu Tomaru**, Toho University Sakura Hospital, Sakura City, Japan

**New Anticoagulation Regimens with Drug-Eluting Stents**

**George Dangas**, Cardiovascular Research Foundation, New York, NY, U.S.A.

**INTERVENTIONAL CARDIOLOGY I**

---

**Evolving Applications of PCI in Patients with Impaired LV Function**

**George W. Vetrovec**, Virginia Commonwealth University, Richmond, VA, U.S.A.

**The Problem of PCI in the Elderly**

**Wolfgang Kubler**, Neckargemund, Germany

**Percutaneous Left Atrial Appendage Closure for Atrial Fibrillation**

**Peter C. Block**, Emory University Hospital, Atlanta, GA, U.S.A.

**PFO Closure for Prevention of Embolic Stroke: 10 Years Experience in >700 Patients**

**Horst Sievert**, Cardiovascular Center Frankfurt/Sankt Katharinen, Frankfurt, Germany

**Excimer Laser Angioplasty in Acute Myocardial Infarction: Evidence-Based Treatment Approach**

**On Topaz**, McGuire VA Medical Center, Division of Cardiology, Richmond, VA, U.S.A.

**Role of Brachytherapy in the Treatment of In-Stent Restenosis in Native Coronary Artery**

**Shirish Jani**, Scripps Clinic & Research Foundation, La Jolla, CA, U.S.A.

**Six Years of Alcohol Septal Ablation for HOCM: Lessons Learned**

**Nasser Lakkis**, Ben Taub General Hospital, Baylor College of Medicine, Houston, TX, U.S.A.

### **Percutaneous Carotid Interventions Under Neuroprotection - an Update 2004**

**Harald Mudra**, Krankenhaus Munchen Neuperlach, Munchen, Germany

### **Drug Eluting Stents in Current Coronary Interventional Practice**

**Verghese Mathew**, Mayo Clinic, Rochester, MN, U.S.A.

### **Primary PCI Versus Thrombolysis in Acute STEMI**

**Deepak Jain**, Universitätsklinikum Lubeck, Lubeck, Germany

### **Paradoxical Embolism - What is the Role of PDO Closure?**

**Arvinder S. Kurbaan**, London Chest Hospital, London, England

### **Advances in Bioengineering and Biomaterials: Improving Interventional Cardiology**

**Steven R. Bailey**, University of Texas Health Sciences Center, San Antonio, TX, U.S.A.

### **Changes in Left Ventricular Function and Stent Patency after PCI in Chronic Total Occlusions**

**Henning Kelbaek**, Rigshospitalet & Skejby Hospital, Denmark



## MANAGEMENT OF CHRONIC ISCHEMIC HEART DISEASE

---

### **Clinicians' Guide for Cardiac Therapy of the Aged**

**Shlomo Stern**, Bikur Cholim Hospital, Jerusalem, Israel

### **Cardioprotection with Ischemic Preconditioning: Is Efficacy Maintained in Aging Cohorts?**

**Karin Przyklenk**, University of Massachusetts Medical School, Worcester, MA, U.S.A.

### **Reducing Cardiovascular Events - Results of New Lipid and HBP Trials**

**Robert DiBianco**, Washington Adventist Hospital, Takoma Park, MD, U.S.A.

### **The Patient with Heart Disease Today and Tomorrow; the Need for a Different Approach in Medical Care**

**Babeth Rabinowitz**, Sheba Medical Center, Tel Hashomer, Israel

### **Is Empathy the Efficient Method for Palliative Cardiology?**

**Herbert Geschwind**, University of Paris, Paris, France

### **Antianginal Therapy and Stress Testing**

**Rosa Sicari**, CNR, Pisa, Italy

### **Women in Cardiac Rehabilitation**

**Vera Bittner**, University of Alabama at Birmingham, Birmingham, AL, U.S.A.

### **New and Evolving Treatment Strategies for Chronic Refractory Angina**

**Greg Barsness**, Mayo Clinic, Rochester, MN, U.S.A.

### **Roles of the Gap Junction in Ischemic Preconditioning Against Myocardial Infarction**

**Tetsuji Miura**, Sapporo Medical University School of Medicine, Sapporo, Japan

## MODIFICATION OF LIPOPROTEINS AND CORONARY DISEASE

---

### **Statin Therapy for High-Risk Normocholesterolemic Patients**

**Clive Rosendorff**, VA Medical Center, Bronx, NY, U.S.A.

### **The Impact of Aggressive Lipid Lowering Therapy in the Elderly**

**Prakash C. Deedwania**, University of California, San Francisco Program, Fresno, CA, U.S.A.

### **Inflammation, CRP and Statins**

**Ishwarlal Jialal**, UC Davis Medical Center, Sacramento, CA, U.S.A.

### **Early Use of Lipid Lowering Drugs in ACS**

**Shmuel Gottlieb**, Bikur Cholim Hospital, Jerusalem, Israel

### **Immune Modulation of Atherosclerosis by Ox-LDL Analogs**

**Dror Harats**, Sheba Medical Center, Tel-Hashomer, Israel

## **HYPERTENSION**

---

### **Rethinking the Primary Prevention of Hypertension**

**Howard D. Sesso**, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.

### **Clinical Applications of Chonocardiology in Hypertension and Heart Failure**

**Adarsh Kumar**, Govt. Medical College/GND Hospital, Amritsar, India

### **The Role of Renin-Angiotensin Antagonists in the Prevention of Atrial Fibrillation in the Patients with Heart Failure and Hypertension**

**Anique Ducharme**, Institut de Cardiologie de Montreal, Montreal, Quebec, Canada

## **DIABETES, METABOLIC SYNDROME AND HEART DISEASE**

---

### **Metabolic Syndrome, Inflammation, and Diet: A Realistic Target**

**Dario Giugliano**, Policlinico della Seconda Universita di Napoli, Napoli, Italy

### **Diagnosing CAD in Diabetic Patients: Myths & Facts**

**Satyendra Giri**, California Heart Institute, Redding, CA, U.S.A.

### **The Role of Life-Style Related Factors on the Prevalence of the Metabolic Syndrome**

**Christos Pitsavos**, University of Athens, Chalandri, Athens, Greece

### **Diabetic Cardiomyopathy: Another Feature of the Metabolic Syndrome?**

**Michaela Diamant**, VU University Medical Center, Amsterdam, The Netherlands

### **Deficiency of a Multi-Ligand Receptor CD36 is Involved in Pathogenesis of the Metabolic Syndrome; Insights from CD36-Deficient Patients**

**Shizuya Yamashita**, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

## **PRIMARY PREVENTION OF CORONARY ARTERY DISEASE**

---

### **The Lifetime Risk of Cardiovascular Diseases: Challenges and Opportunites for Clinical and Public Health Action**

**George A. Mensah**, Center for Disease Control and Prevention, Atlanta, GA, U.S.A.

### **What is an Optimal Diet?**

**Dean Ornish**, Preventive Medicine Research Institute, Sausalito, CA, U.S.A.

### **Cardiovascular Risk Profile Earlier in Life and Health Care Costs in Older Age**

**Martha L. Daviglus**, Feinberg School of Medicine, Northwestern University, Chicago, IL, U.S.A.

### **Longitudinal Weight Control in a Cardiology Practice**

**Yzhar Charuzi**, Cedars Sinai Medical Center, Los Angeles, CA, U.S.A.

### **The Cardiovascular Research of Herb and Natural Products**

**Paul Chan**, TMU-Wan Fang Hospital, Taipei, Taiwan-R.O.C.

## **DILATED CARDIOMYOPATHY: VARIOUS ETIOLOGIES I**

---

### **Obesity Cardiomyopathy: Pathogenesis, Clinical Recognition and Management**

**Martin A. Alpert**, St. John's Mercy Medical Center, St. Louis, MO, U.S.A.

### **Diagnosis and Treatment of Inflammatory Cardiomyopathy**

**Heinz-Peter Schultheiss**, University Hospital Benjamin Franklin, Berlin, Germany

### **The Role of Oxidative Stress in Myocardial Remodeling and Failure**

**Hiroyuki Tsutsui**, Kyushu University Graduate School of Medical Science, Higashi-ku, Fukuoka, Japan

### **Modulation of Adriamycin II Induced Apoptosis in Cardiomyocytes**

**Pawan K. Singal**, University of Manitoba, Winnipeg, Manitoba, Canada

### **Collagen and Cardiovascular Remodeling. Why Bother?**

**Bodh I. Jugdutt**, University of Alberta Hospitals, Edmonton, Alberta, Canada

### **Idiopathic Dilated Cardiomyopathy: An "Ischemic" Myocardial Disease?**

**Danilo Neglia**, CNR, Institute of Clinical Physiology, Pisa, Italy

## **DILATED CARDIOMYOPATHY: VARIOUS ETIOLOGIES II**

---

### **Prognostic Factors and Risk Stratification in Chagas' Heart Disease**

**Anis Rassi Jr.**, Anis Rassi Hospital, Goiania, GO, Brazil

### **Dobutamine-Induced Hypersensitivity Myocarditis in End-Stage Heart Failure Patients**

**Charles Y. Lui**, University of Arizona Health Sciences Center, Tucson, AZ, U.S.A.

### **HIV Infection and the Cardiovascular System**

**Giuseppe Barbaro**, University of Rome "La Sapienza", Rome, Italy

### **Fabry Cardiomyopathy: Diagnosis and Treatment**

**Andrea Frustaci**, Catholic University, Rome, Italy

### **The Role of Calcium Channels in Iron-Overload Cardiac Dysfunction and Cardiomyopathy**

**Peter H. Backx**, University of Toronto, Toronto, Ontario, Canada

### **Sex, Lies and Heart Failure**

**Manuel Martínez-Selles**, University Hospital Gregorio Marañón, Madrid, Spain

### **Prevention of Dilated Cardiomyopathy in Cases of Coxsackie B Viral Myocarditis**

**Nodar N. Kipshidze**, Institute of Experimental and Clinical Therapy, Tbilisi, Rep. of Georgia

## **PREDICTORS AND MARKERS OF HEART FAILURE OUTCOME**

---

### **Biomarkers in Cardiomyopathy**

**Wayne Miller**, Mayo Clinic, Rochester, MN, U.S.A.

### **Echocardiography and BNP in the Diagnosis and Prognosis of Congestive Heart Failure**

**Hisham Dokainish**, Baylor College of Medicine, Houston, TX, U.S.A.

### **BNP: Effects Beyond the Kidneys**

**Hans Peter Brunner-La Rocca**, University Hospital Basel, Basel, Switzerland

## **LEFT VENTRICULAR HYPERTROPHY AND HYPERTROPHIC CARDIOMYOPATHY**

---

### **Endocardial Radiofrequency Ablation for HOCM: a New Technique of Catheter Based Treatment for HOCM**

**T. Lawrenz**, The Bielefeld Klinikum, Bielefeld, Germany

### **Differentiation Between Physiological Left Ventricular Hypertrophy and Hypertrophic Cardiomyopathy in Highly Trained Athletes**

**Sanjay Sharma**, University Hospital Lewisham, London, England

## **ROLE OF THE PERICARDIUM**

---

### **Contemporary Diagnostic Algorithm for Pericardial Diseases: Lessons to be Learned From the First European Guidelines**

**Petar M. Seferovic**, Institute for Cardiovascular Diseases, Belgrade, Yugoslavia

## **DIASTOLIC DYSFUNCTION**

---

### **An Animal Model of Diastolic Heart Failure; Implication of Medical Treatment**

**Masatsugu Hori**, Osaka University School of Medicine, Osaka, Japan

**Assessment of Left Ventricular Diastolic Function: Role of Echocardiographic Techniques**

**Sherif Nagueh**, Baylor College of Medicine, Houston, TX, U.S.A.

## **PULMONARY HYPERTENSION**

---

**Vasoactive Intestinal Peptide -- A New Treatment for Pulmonary Hypertension**

**Israel Rubinstein**, University of Illinois College of Medicine, Chicago, IL, U.S.A.

**Cardiac Biomarkers in Pulmonary Embolism and Pulmonary Hypertension**

**Ijaz A. Khan**, University of Maryland School of Medicine, Baltimore, MD, U.S.A.

## **EXERCISE PHYSIOLOGY IN HEART FAILURE**

---

**The Muscle Hypothesis in Chronic Heart Failure: Myth or Fact?**

**Massimo Piepoli**, "Guglielmo da Saliceto" Hospital, Piacenza, Italy

## **RENAL ASPECTS**

---

**Cardiorenal Syndrome and Heart Failure**

**Uri Elkayam**, USC School of Medicine, Los Angeles, CA, U.S.A.

**Cardiovascular Disease in Renal Failure: An Overview**

**Rene R. Wenzel**, University Hospital Essen, Essen, Germany

**Renal Angioplasty and Stenting Under Protection: The Way for the Future?**

**Michel Henry**, Cabinet de Cardiologie, Nancy, France

## **NEW HORIZONS IN THE MANAGEMENT OF HEART FAILURE**

---

**Interstitial Unraveling of the Matrix in Heart Failure: Clinical Implications**

**Francis G. Spinale**, Medical University of South Carolina, Charleston, SC, U.S.A.

**Acute Heart Failure Syndrome**

**Mihai Gheorghiade**, Northwestern University, Chicago, IL, U.S.A.

**The Pursuit of Optimum Outcomes in Heart Failure: Polypharmacy and Devices for All or Selective Use**

**Udho Thadani**, University of Oklahoma HSC, Oklahoma City, OK, U.S.A.

**Novel Drug Therapies for Heart Failure**

**Robert E. Hobbs**, The Cleveland Clinic Foundation, Cleveland, OH, U.S.A.

**New Device Therapies and Monitoring Devices for Advanced Heart Failure**

**Robert C. Bourge**, The University of Alabama, Birmingham, AL, U.S.A.

**Strategies to Achieve Reverse Remodeling -- Current and Emerging Therapies**

**Mitchell T. Saltzberg**, Midwest Heart Specialists, Downers Grove, IL, U.S.A.

**Relevance of Beta-blocker Therapy in Inflammatory Heart Disease**

**Matthias Pauschinger**, University Hospital Benjamin Franklin, Berlin, Germany

**Use of ARBs in the Management of CHF**

**Mario F. C. Maranhao**, Curitiba, PR, Brazil

**ARRHYTHMIAS I: SUDDEN CARDIAC DEATH / CARDIOPULMONARY  
RESUSCITATION / IMPLANTABLE ANTIARRHYTHMIC DEVICES**

---

**Risk Stratification for Sudden Death--Is Ejection Fraction Alone Sufficient?**

**Michael E. Cain**, Washington University School of Medicine, St. Louis, MO, U.S.A.

**Do All Patients With CAD and an EF <30% Need a Defibrillator?**

**Douglas L. Packer**, Mayo Clinic, Rochester, MN, U.S.A.

**Minimizing Ventricular Pacing in an ICD**

**Brian Olshansky**, University of Iowa Hospital and Clinics, Iowa City, Iowa, U.S.A.

**Indications for ICD Implantation - Guidelines for the Clinician**

**C. Thomas Peter**, Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.

**The Fully Automatic External Cardioverter-Defibrillator: The Reality of a New  
Meaningful Scenario**

**Antonio Martinez-Rubio**, Hospital de Sabadell (Parc Tauli), Sabadell, Spain

**The Identification of Heart Failure Patients Prone to Benefit from Cardiac  
Resynchronization Therapy**

**Maria Vittoria Pitzalis**, University of Bari, Bari, Italy

**Pacing Therapy: Lessons Learned from Multicenter Clinical Studies**

**Paul A. Levine**, St. Jude Medical CRMD, Sylmar, CA, U.S.A.

**5 Year Follow up of Patients Following CRT**

**Thomas A. Mabin**, South African Society of Cardiovascular Intervention, Somerset West,  
South Africa

**Sleep Apnea, Cardiac Arrhythmias and Sudden Cardiac Death**

**Virend K. Somers**, Mayo Clinic, Rochester, MN, U.S.A.

**Short QT Syndrome: a New Cause of Both Sudden Death and Atrial Fibrillation**

**Fiorenzo Gaita**, Ospedale Mauriziano di Torino, Italy

## ARRHYTHMIAS II: DIAGNOSIS / DRUG THERAPY / ABLATION

---

### **Interatrial Block -- Forerunner of Atrial Fibrillation: A Poorly Perceived Pandemic**

**David H. Spodick**, Saint Vincent Hospital-Worcester Medical Center, Worcester, MA, U.S.A.

### **Asymptomatic or "Silent" Atrial Fibrillation**

**Richard L. Page**, University of Washington School of Medicine, Seattle, WA, U.S.A.

### **Pharmacological Therapy of Atrial Fibrillation: First or Last Solution?**

**Alessandro Capucci**, Ospedale "Guglielmo da Saliceto", Piacenza, Italy

### **Arrhythmogenic Effects of Illicit Drugs in Athletes**

**Francesco Furlanello**, Istituto Policlinico San Donato Milanese--Milan, Trento, Italy

### **Atrial Fibrillation and Ventricular Dysfunction: A Vicious Cycle**

**Win-Kuang Shen**, Mayo Clinic, Rochester, MN, U.S.A.

### **The Future of Pulmonary Vein Ablation**

**Peter G. Guerra**, Montreal Heart Institute, Montreal, Quebec, Canada

### **Temporal Patterns of Cardiac Arrhythmias**

**Mark Wood**, Medical College of Virginia, Richmond, VA, U.S.A.

### **Mechanism of Atrial Thrombus Formation**

**Shinya Goto**, Tokai University School of Medicine, Isehara, Kanagawa, Japan

### **Electrocardiographic J Wave and J Wave Syndromes**

**Gan-Xin Yan**, Main Line Health Heart Center, Wynnewood, PA, U.S.A.

## VALVULAR HEART DISEASE / HEART VALVE SURGERY / DISEASES OF THE THORACIC AORTA

---

### **Valvular Heart Disease: Relation of Extracellular Matrix Variation, Contractility and Clinical Outcome**

**Jeffrey S. Borer**, The New York Hospital, Cornell Medical Center, New York, NY, U.S.A.

### **Aortic Dysfunction: Clinical Implications**

**Harisios Boudoulas**, Academy of Athens, Athens, Greece

### **Immediate Precipitating Events Leading to Aortic Dissection**

**John A. Elefteriades**, Yale University School of Medicine, New Haven, CT, U.S.A.

### **Percutaneous Mitral Valve Repair**

**Timothy A. Sanborn**, Evanston Northwestern Healthcare, Evanston, IL, U.S.A.

### **Mitral Valve Repair in Patients with End-Stage Cardiomyopathy: Who Will Benefit?**

**Dan M. Meyer**, University of Texas Southwestern Medical Center, Dallas, TX, U.S.A.

### **Osteoblastogenesis in Aortic Valve Disease**

**Nalini M. Rajamannan**, Northwestern University Feinberg School of Medicine, Chicago, IL, U.S.A.

### **Patient-Prosthesis Mismatch: Definition, Clinical Significance and Prevention**

**Philippe Pibarot**, Laval University, Sainte Foy, Quebec, Canada

## PEDIATRIC CARDIOLOGY AND ADVANCES IN CONGENITAL HEART DISEASE

---

### **Angiogenic Ability of Children with Kawasaki Disease**

**Masaru Terai**, Graduate School of Medicine, Chiba University, Chuo-ku, Chiba-shi, Chiba, Japan

### **Latest Developments in Pediatric Mechanical Circulatory Support**

**Brian W. Duncan**, The Children's Hospital at the Cleveland Clinic, Cleveland, OH, U.S.A.

### **Role of Maternal Nutrition in the Fetal Cardiac Development**

**Pram S. Tappia**, St. Boniface Hospital Research Centre, Winnipeg, Manitoba, Canada

### **Outcomes for Adults with Congenital Heart Disease**

**Geoffrey Rosenthal**, The Children's Hospital at the Cleveland Clinic, Cleveland, OH, U.S.A.

### **Tetralogy of Fallot: Ventricular Dysfunction and Electrical Instability after Surgical Correction**

**Luciano Daliento**, University of Padua, Padova, Italy

### **Pathogenesis and Management of Aortic Dilation in Adults with Congenital Heart Disease**

**Angela T. Yetman**, The Children's Hospital, Denver, CO, U.S.A.



## NEW APPROACHES TO SURGICAL REVASCULARIZATION

---

### **Surgery for End-Stage Coronary Disease**

**Keith A. Horvath**, CVB, NHLBI, NIH, Bethesda, MD, U.S.A.

### **Operative Risk Factor Analysis of Coronary Artery Bypass Grafting in Diabetics**

**Patrick Nataf**, Center Cardiologique du Nord, Saint Denis, France

### **Reduction of Infarct Size by Microaxial Blood Pumps**

**Bart Meyns**, Gasthuisberg University Hospital, Leuven, Belgium

### **Advances in Cardiac Surgery**

**Mercedes, K. C. Dullum**, Washington Regional Cardiac Surgery PC, Washington DC, U.S.A.

## **SURGERY FOR LV DYSFUNCTION, CARDIAC TRANSPLANTATION, MECHANICAL SUPPORT**

---

### **Candidate Selection for Left Ventricular Assist Device Therapy**

**Geetha Bhat**, University of Louisville and Jewish Hospital, Louisville, KY, U.S.A.

### **Cardiac Allograft Vasculopathy -- Is There Finally Some Light at the End of the Tunnel?**

**Maryl R. Johnson**, University of Wisconsin Medical School, Madison, WI, U.S.A.

### **Retransplantation After Heart Transplantation for Graft Vessel Disease: Prevention Strategies and Outcome**

**Bruno M. Meiser**, University of Munich, Klinikum Grosshadern, Munich, Germany

### **New Techniques in Surgery for Heart Failure**

**Jai Raman**, The University of Chicago Medical Center, Chicago, Illinois, U.S.A.

### **Surgical Treatment of Heart Failure - from Valve Repair to Repair of the Ventricle**

**Ninoslav Radovanovic**, University Clinic of Cardiovascular Surgery, Sremska Kamenica, Novi Sad, Yugoslavia

### **Extended Heart Allograft Survival by Manipulation of Vascular Endothelium to Express Fas-Ligand**

**Nadir Askenasy**, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

### **Transplant Coronary Artery Disease: Incidence, Progression and Interventional Revascularization**

**Suzanne Roedler**, University of Vienna, Vienna, Austria